The Importance of physical activity in the treatment of hemophilia
DOI:
https://doi.org/10.12775/QS.2024.21.54094Keywords
hemophilia, physical activity, excercises, hemophilic arthropathyAbstract
Hemophilia is a genetically determined bleeding disorder characterized by a tendency for spontaneous bleeding, mainly into the joints, which can lead to arthropathy and significantly reduce the quality of a patient's life. The objective of this paper is to review the published literature on the impact of physical activity on the course of the disease and its role in current therapeutic protocols. Online databases were used to search for literature. The retrieved articles were analyzed. The review mainly included literature published after 2016. In the past, physical exercise was not recommended for people with hemophilia, primarily due to concerns about joint bleeding and the development of hemophilic arthropathy. Currently, regular, moderate physical activity plays a crucial role in the management of hemophilia, helping to strengthen muscles and improve joint stability, which can reduce the risk of bleeding. This shift in perspective is largely due to the availability of effective therapeutic options, mainly involving the replacement clotting factors. However, entirely new hopes for a permanent cure and the maintenance of physical fitness are brought by modern gene therapy treatments. Physical activity is essential for maintaining the health and fitness of individuals with hemophilia, and most exercises are safe due to effective prophylactic treatment. In addition to the benefits for joint health, regular exercise also helps prevent many lifestyle-related diseases.
References
Tsukasa Ohmori. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. International Journal of Hematology. 2020; 111:31–41. https://doi.org/10.1007/s12185-018-2513-4
Rodríguez-Merchán E.C et al. Gene Therapy in Hemophilia: Recent Advances. Int. J. Mol. Sci. 2021; 22:7647. https://doi.org/10.3390/ijms22147647
Marchesini E et al. Recent Advances in the Treatment of Hemophilia: A Review. Biologics: Targets and Therapy. 2021:15:221–235. https://doi.org/10.2147/BTT.S252580
Miesbach W et al. Gene Therapy for Hemophilia - Opportunities and Risks. Dtsch Arztebl Int. 2022; 119: 887–94. https://doi.org/10.3238/arztebl.m2022.0353
Benemei S et al. Outcome measures in hemophilia: current and future perspectives. Expert Review of Hematology. 2024:17(7); 329-340. https://doi.org/10.1080/17474086.2024.2365929
Pipe S.W et al. Hemophilia A gene therapy: current and next generation approaches. Expert Opinion on Biological Therapy. 2022:22(9);1099-115. https://doi.org/10.1080/14712598.2022.2002842
Srichumpuang C et al. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis. Srichumpuang et al. Orphanet Journal of Rare Diseases. 2024;19:135. https://doi.org/10.1186/s13023-024-03092-2
Thornburg C.D et al. The benefits of gene therapy in people with haemophilia. J Viral Hepat. 2024;31(Suppl. 1):4–8. https://doi.org/10.1111/jvh.13882
Owsianowska J. The evaluation of the quality of life in patients with haemophilia. Pomeranian J Life Sci. 2017;63(1):11-19. https://doi.org/10.21164/pomjlifesci.220
Kaczmarek R. Gene therapy of haemophilia – has the cure come within reach? Postępy Biochemii. 2018;64(4). https://doi.org/10.18388/pb.2018_145
Trinchero A et al. The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges. Hämostaseologie. 2020;40:311–321. https://doi.org/10.1055/a-1175-6530
Sangeeta, Dimple Choudhry et al. Effect of Exercise on Muscle Strength, Pain and Functional Ability in Patients with Haemophilia: A Narrative Review. International Journal of Science and Research. 2024;13(1). https://dx.doi.org/10.21275/SR24101122713
Xin Wang et al. The hemophilia quality of life scale: a systematic review. Front. Public Health. 2024;12:1294188. https://doi.org/10.3389/fpubh.2024.1294188
Gorecka A et al. Uszkodzenie stawów w przebiegu artropatii hemofilowej jako wyzwanie diagnostyczne i terapeutyczne. Postępy w diagnostyce medycznej. 2020.
Amit C. Nathwani. Gene therapy for hemophilia. Hematology Am Soc Hematol Educ Program. 2022(1):569-578. https://doi.org/10.1182/hematology.2022000388
Pier Mannuccio Mannucci. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545-553. https://doi.org/10.3324/haematol.2019.232132
Windyga J. Advances in the treatment of patients with hemophilias. Hematologia. 2015;6(1): 97–102. https://doi.org/10.5603/Hem.2015.0021
Leebeek F, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021; Sep 16;138(11):923-931. https://doi.org/10.1182/blood.2019003777
Oldenburg J et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017;377:809-18. https://doi.org/10.1056/NEJMoa1703068
Nogami K et al. Association of physical activity with bleeding events and safety in patients with haemophilia A starting emicizumab prophylaxis: an interim analysis of the TSUBASA study. International Journal of Hematology. 2024;119:14–23. https://doi.org/10.1007/s12185-023-03679-8
Miesbach W. et al. Treatment Options in Hemophilia. Dtsch Arztebl Int. 2019;116: 791–800. https://doi.org/10.3238/arztebl.2019.0791
Chira S. et al. Progresses towards safe and efficient gene therapy vectors. Oncotarget. 2015 Oct 13;6(31): 30675–30703. https://doi.org/10.18632/oncotarget.5169
Sekayan T et al. Etranacogene dezaparvovec-drlb gene therapy for patients with hemophilia B (congenital factor IX deficiency). Expert Opinion on Biological Therapy. 2023;12:1173-1184. https://doi.org/10.1080/14712598.2023.2282138
Samelson-Jones BJ et al. Roctavian Gene Therapy for Hemophilia A. Blood Advances. 2024. https://doi.org/10.1182/bloodadvances.2023011847
Kohn DB et al. Successes and challenges in clinical gene therapy. Gene Therapy. 2023;30:738–746. https://doi.org/10.1038/s41434-023-00390-5
Anguela X, High K. Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec. Blood Advances. 2024;6(7):1796- 1803. https://doi.org/10.1182/bloodadvances.2023010511
Maffet M, Rotton J Jr. Hemophilia in Sports: A Case Report and Prophylactic Protocol. Journal of Athletic Training. 2017;52(1):65–70. https://doi.org/10.4085/1062-6050-51.11.14
Bérubé S et al. Illness perceptions and their relation to physical activity in children and adolescents with hemophilia. Health Psychology and Behavioral Medicine.2020;8(1):461-474. https://doi.org/10.1080/21642850.2020.1823226
Shrestha A et al. Physical activity and bleeding outcomes among people with severe hemophilia on extended half-life or conventional recombinant factors. Res Pract Thromb Haemost. 2021;5:94–103. https://doi.org/10.1002/rth2.12437
Alshimaa R. Azab et al. Adolescents with hemophilic knee arthropathy can improve their gait characteristics, functional ability, and physical activity level through kinect-based virtual reality: A randomized clinical trial. Heliyon. 2024. 10(7):E28113. https://doi.org/10.1016/j.heliyon.2024.e28113
Gualtierotti R, Solimeno LP, Peyvandi F. Hemophilic arthropathy: Current knowledge and future perspectives. J Thromb Haemost. 2021;19:2112–2121. https://doi.org/10.1111/jth.15444
Ucero-Lozano R et al. Changes in Quality of Life, Adherence, and Kinesiophobia in Patients with Hemophilia Treated with Extended Half-Life Treatment: Final Results of the LongHest Project. Pharmaceuticals. 2024;17:835. https://doi.org/10.3390/ph17070835
Mancuso ME et al. Physical Activity, Bleedings and Quality of Life in Subjects with Haemophilia A without Inhibitors—A Multicenter, Observational Italian Study with a Wearable Device. J. Clin. Med. 2024; 13: 3036. https://doi.org/10.3390/jcm13113036
Moretti L et al. Sports and Children with Hemophilia: Current Trends. Children. 2021;8:1064. https://doi.org/10.3390/children8111064
Pérez-Alenda S et al. Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up. Haemophilia. 2024;30:791–799. https://doi.org/10.1111/hae.14988
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Kinga Ziojła-Lisowska, Aleksandra Cieplińska, Agnieszka Kuzio, Grzegorz Jama
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 119
Number of citations: 0
